Novo Nordisk's share price fell by as much as 7% on Monday after the company unveiled new growth ambitions aimed at reinvigorating its position in the booming obesity drug market. The company plans to launch more than five drugs with "multiple blockbuster" potential by 2030 and expects to achieve over DKK 150 billion (approximately $23 billion) in R&D pipeline sales by 2035. Additionally, Novo Nordisk anticipates revenue growth from 2026 to 2030 to be in line with industry peers.